Visit booth 1921 to learn about LumiThera, Inc. and Valeda.
LumiThera, Inc. is committed to creating brighter horizons for patients by developing treatment solutions utilizing multiwavelength photobiomodulation to improve visual function, to stop or slow the progression of debilitating eye diseases, and to prevent vision loss and blindness.
LumiThera’s first product, Valeda Light Delivery System, is the first approved treatment for Dry Age-Related Macular Degeneration using Photobiomodulation in Europe. Valeda improves visual acuity, improves contrast sensitivity, reduces central drusen volume, and is designed for ease-of-use in the clinician’s office.
Valeda is CE Marked in the Europe Union. Valeda is in clinical trials and not approved for use in the United States. Visit https://lumithera.com to learn more.
Brands: The Valeda LIght Delivery System is the first approved treatment for Dry AMD using Photobiomodulation in the EU. Valeda is in clinical trials and not approved for use in the United States.